PaxMedica Statistics
Total Valuation
PaxMedica has a market cap or net worth of $5.68 million. The enterprise value is $969,955.
| Market Cap | 5.68M |
| Enterprise Value | 969,955 |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PaxMedica has 7.47 million shares outstanding. The number of shares has increased by 223.37% in one year.
| Shares Outstanding | 7.47M |
| Shares Change (YoY) | +223.37% |
| Shares Change (QoQ) | +71.12% |
| Owned by Insiders (%) | 8.14% |
| Owned by Institutions (%) | 1.60% |
| Float | 6.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.16, with zero debt.
| Current Ratio | 3.16 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,994.61 |
Financial Efficiency
Return on equity (ROE) is -956.80% and return on invested capital (ROIC) is -476.95%.
| Return on Equity (ROE) | -956.80% |
| Return on Assets (ROA) | -388.90% |
| Return on Capital (ROIC) | -476.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.05M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.51% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -97.51% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 3.87 |
| Relative Strength Index (RSI) | 58.96 |
| Average Volume (30 Days) | 2,410,869 |
Short Selling Information
The latest short interest is 133,720, so 1.79% of the outstanding shares have been sold short.
| Short Interest | 133,720 |
| Short Previous Month | 552,325 |
| Short % of Shares Out | 1.79% |
| Short % of Float | 1.94% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.15M |
| Pretax Income | -18.29M |
| Net Income | -18.29M |
| EBITDA | -18.28M |
| EBIT | -18.28M |
| Earnings Per Share (EPS) | -$11.00 |
Balance Sheet
The company has $4.71 million in cash and no debt, giving a net cash position of $4.71 million or $0.63 per share.
| Cash & Cash Equivalents | 4.71M |
| Total Debt | n/a |
| Net Cash | 4.71M |
| Net Cash Per Share | $0.63 |
| Equity / Book Value | 3.39M |
| Book Value Per Share | 0.45 |
| Working Capital | 3.89M |
Cash Flow
| Operating Cash Flow | -10.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | -10.77M |
| FCF Per Share | -$6.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PaxMedica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -223.37% |
| Shareholder Yield | -223.37% |
| Earnings Yield | -321.97% |
| FCF Yield | -189.57% |
Analyst Forecast
The average price target for PaxMedica is $3.00, which is 294.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 294.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 31, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | Oct 31, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |